PRIMROSE TISSUE STUDY: A COLLECTION AND ANALYSIS OF TISSUE AND CSF SAMPLES FROM PATIENTS WITH CNS DISEASE SECONDARY TO BREAST CANCER

Study ID: 47662
Short Title: PRIMROSE Tissue: Collection and Analysis of samples in breast cancer
Trust Name: UHS
Recruitment Site: Southampton General Hospital
Disease Area: Breast cancer
Phase: N/A
Expected End Date: 30/09/2024
Postcode: SO16 6YD
Contact Name: Amanda Pattie
Contact Email: studysupport1and3.crnwessex@nihr.ac.uk
Active: Yes

Inclusion criteria, exclusion criteria and study summary

1.Male or female. 2.16 years of age or above 3.Histologically and/or cytologically confirmed breast cancer with CNS involvement, as defined as having one or more of the following: a)Metastases to the brain parenchyma b)Metastases to the leptomeninges c)Paraneoplastic Neurological Disorders 4.FFPE of biopsied or resected primary breast cancer, non-CNS metastasis and/ or brain metastasis is available or will be available. 5.Informed consent

1.Unable to comply with study procedures or give informed consent

PRIMROSE Tissue Study aims to collect and investigate archived tissue, excess CSF samples and related data (all collected as part of standard care) from patients with central nervous system disease secondary to breast cancer. This study does not involve additional procedures or interventions outside of standard care. Patients will be informed of the study and consented to participate in PRIMROSE Tissue. Following consent, arrangements will be made to request available archived FFPE tissue blocks of primary breast cancer tissue, non-cranial metastatic tissue or cranial metastatic tissue if available. CSF samples will be collected only if the patient has been scheduled to undergo a CSF collection procedure as part of their standard care. In this case, an excess 10ml of CSF will be collected for the PRIMROSE Tissue study. Prior to CSF collection, 10ml blood will be collected for the study (which would not otherwise be collected). The study can be carried out by trained clinical staff members, at sites with the appropriate and relevant facilities and this study does not involve experimental treatment or placebo treatment.

Study MapList of studies

Accessibility tools

Return to header